natgillin/translations-raw huggingface dataset:
Choose an area of your body for the injection (injection site)
Izberite predel telesa, kamor si boste injicirali zdravilo (mesto injiciranja)
Choose an infusion site(s) in either the middle to upper abdomen or thigh.
Izberite mesto(a) infundiranja bodisi na sredini ali zgornjem delu trebuha bodisi na stegnu.
Choose an injection site
Izberite mesto za injiciranje
Choose an injection site (see Figure 2)
Izberite injekcijsko mesto (glejte Sliko 2)
Choose an injection site (thighs, abdomen, arms, buttocks).
Izberite mesto injiciranja (stegna, trebuh, roke, zadnjica).
Choose an injection site and wipe your skin with an alcohol wipe.
Izberite mesto injiciranja in kožo obrišite z alkoholnim robčkom.
Choose an injection site in the area your doctor or nurse has told you to give the injection.
6.1. Izberite mesto, kamor boste dali injekcijo na predelu, ki vam ga je svetoval zdravnik ali medicinska sestra.
Choose an injection site on your stomach area (abdomen) or thigh.
Izberite mesto za injiciranje v predelu trebuha ali na stegnu.
Choose an injection site.
Izberite mesto injiciranja.
Choose an injection site.
Izberite mesto za injiciranje.
Choose and prepare the injection site:
Izberite in pripravite injekcijsko mesto:
Choose different sites for these injections and give the injections one right after the other.
Izberite različni mesti za injiciranje in si injicirajte injekciji eno za drugo.
Choose he appropriate option listed below for giving REYATAZ oral powder to your child.
Izberite enega od v nadaljevanju navedenih načinov dajanja zdravila REYATAZ peroralni prašek, ki ustreza otroku.
Choose healthy, unbroken skin (non-irritated and non- irradiated skin) site on the chest or upper outer arm ONLY.
Izberite zdravo, nepoškodovano kožo (nerazdraženo in neobsevano) SAMO na prsih ali zunanjem delu nadlahti.
Choose one day of the month that will be easy to remember.
Izberite dan v mesecu, ki si ga boste zlahka zapomnili.
Choose one day of the month that will be easy to remember.
Izberite si dan v mesecu, ki si ga boste lahko zapomnili.
Choose one of the recommended injection sites as shown.
Izberite eno od priporo enih mest injiciranja, kot je prikazano.
Choose one of these places:
Izberite eno od naslednjih mest:
Choose the correct Plegridy pen from a pack.
Iz pakiranja izberite pravilen napolnjen injekcijski peresnik zdravila Plegridy.
Choose the correct Plegridy pre-filled syringe from a pack.
Iz pakiranja izberite pravilno napolnjeno injekcijsko brizgo zdravila Plegridy.
Choose the injection site (Figure F)
Izberite mesto injiciranja (slika F)
Choose the injection site.
Izberite mesto injiciranja.
Choose the oral dispenser based on dose:
Odmernik izberite glede na velikost odmerka:
Choose the place to give the injection – where your doctor or nurse has told you.
Izberite mesto, kamor boste dali injekcijo – kakor vam je svetoval vaš zdravnik ali medicinska sestra.
Choose your injection site in either your stomach, thigh, or back of the arm.
Izberite mesto za injiciranje, ki je lahko na trebuhu, stegnu ali zadnji strani nadlakti.
Choosing and preparing an injection site
Izbira in priprava injekcijskega mesta
Choosing and preparing an injection site
Izbira in priprava injekcijskega mesta zdravila Humira
Choosing and preparing the injection site
Izbira in priprava mesta za injiciranje
Choreoathetosis, dyskinesia, hyperkinesia
horeoatetoza, diskinezija, hiperkinezija
Choreoathetosis,d yskinesia, hyperkinesia
horeoatetoza, diskinezija, hiperkinezija
Choriogonadotropin alfa
Horiogonadotropin alfa
Choriogonadotropin alfa is similar to a hormone found naturally in your body called ‘chorionic gonadotropin’, which is involved in reproduction and fertility.
Horiogonadotropin alfa je podoben naravnemu človeškemu hormonu, imenovanem "horionski gonadotropin", ki sodeluje pri razmnoževanju in plodnosti.
Chorionic gonadotropin binds on the ovarian theca (and granulosa) cells to a transmembrane receptor shared with the luteinising hormone, the LH/CG receptor.
Horionski gonadotropin se na celicah teke (in granuloze) jajčnikov veže na transmembranski receptor LH/CG, ki je skupen luteinizirajočemu hormonu in hCG.
Chorioretinopathy
horioretinopatija
Choroidal detachment
Odstopanje žilnice
CHR (95% CI)
Popoln
CHR rate n (%)
534 (96,6 %)
CHR: ANC > 1.5 x 109/l, platelets >100x109/l, no blood blasts, BM blasts <5% and no extramedullary disease
CHR ANC  1,5 x 109/l, trombociti  100 x 109/l, brez blastov v krvi, BM blasti < 5 % in brez
CHR: ANC > 1.5 x 109/l, platelets >100x109/l, no blood blasts, BM blasts <5% and no extramedullary disease
CHR ANC  1,5 x 109/l, trombociti  100 x 109/l, brez blastov v krvi, BM blasti < 5 % in brez obolelosti zunaj kostnega mozga
CHR: Study 0110 [WBC < 10 x 109/l, platelets < 450 x 109/l, myelocyte+metamyelocyte < 5% in blood, no blasts and promyelocytes in blood, basophils < 20%, no extramedullary involvement] and in studies 0102 and 0109 [ANC ≥ 1.5 x 109/l, platelets ≥ 100 x 109/l, no blood blasts, BM blasts < 5% and no extramedullary disease]
CHR študija 0110 [WBC < 10 x 109/l, trombociti < 450 x 109/l, mielociti+metamielociti < 5 % v krvi, brez blastov in promielocitov v krvi, bazofilci < 20 %, brez prizadetosti zunaj kostnega mozga] in v študijah 0102 in 0109 [ANC ≥ 1,5 x 109/l, trombociti ≥ 100 x 109/l, brez blastov v krvi, BM blasti < 5 % in brez bolezni zunaj kostnega mozga]
CHR: Study 0110 [WBC < 10 x 109/l, platelets < 450 x 109/l, myelocyte+metamyelocyte < 5% in blood, no blasts and promyelocytes in blood, basophils < 20%, no extramedullary involvement] and in studies 0102 and 0109 [ANC  1.5 x 109/l, platelets  100 x 109/l, no blood blasts, BM blasts < 5% and no extramedullary disease]
CHR študija 0110 [WBC < 10 x 109/l, trombociti < 450 x 109/l, mielociti+metamielociti < 5 % v krvi, brez blastov in promielocitov v krvi, bazofilci < 20 %, brez prizadetosti zunaj kostnega mozga] in v študijah 0102 in 0109 [ANC  1,5 x 109/l, trombociti  100 x 109/l, brez blastov v krvi, BM blasti < 5 % in brez bolezni zunaj kostnega mozga]
Chromaturia
kromaturija
Chromaturia
zmanjšanje telesne
Chromaturia (blue- green urine discolouration) has been reported with zaleplon overdose.
Pri prevelikem odmerjanju zaleplona so poročali o kromaturiji (modro-zelena obarvanost urina).
Chromaturia (blue-green)
kromaturija (modrozeleno)
Chromaturia (see above).
Kromaturija (glejte zgoraj).
Chromaturia, Nocturia
kromaturija, nikturija
chromaturia.
kromaturija
chromoblastomycosis and mycetoma (long-term fungal infections of the skin or the tissue just below the skin, usually caused by fungal spores infecting wounds due to thorns or splinters), coccidioidomycosis (fungal infection of the lungs caused by breathing in spores).
kromoblastomikoza in micetom (dolgotrajni glivični okužbi kože in podkožnega tkiva, ki ju navadno povzročajo glivične spore, ki okužijo rane, ki jih povzročijo trni ali trske), kokcidioidomikoza (glivična okužba pljuč, ki jo povzroča vdihavanje spor).
chromoblastomycosis and mycetoma (long-term fungal infections of the skin or the tissue just below the skin, usually caused by fungal spores infecting wounds due to thorns or splinters), coccidioidomycosis (fungal infection of the lungs caused by breathing in spores).
kromoblastomikoze in micetoma (dolgotrajnih glivičnih okužb kože in podkožnega tkiva, ki ju navadno povzročajo glivične spore, ki okužijo nastale rane zaradi trnov ali trsk), kokcidioidomikoze (glivične okužbe pljuč, ki jo povzroča vdihavanje spor).
Chromoblastomycosis/Mycetoma: 9 of 11 patients were successfully treated with posaconazole
Kromoblastomikoza ali micetom: 9 od 11 bolnikov je bilo uspešno zdravljenih s posakonazolom
Chromogenic assay
Kromogeni preizkus
Chromogenic assay Mean ± SD
20,4 ± 6,9
Chromogenic assay Mean ± SD
Povprečje ± SD
Chromogenic assay results Median; (Q1; Q3) (IU/dL / IU/kg)
Izsledki kromogenega testa Mediana; (Q1; Q3) (i.e./dl / i.e./kg)
Chromogenic assay results Median; (Q1; Q3) (IU/dL / IU/kg)
Niðurstöður úr litmyndunargreiningu Miðgildi; (Q1; Q3) (a.e./dl / a.e./kg)
Chromosomal aberrations were categorized according to Döhner’s hierarchical model.
Kromosomske spremembe so bile razvrščene glede na Döhnerjev hierarhični model.
chronic (long-term) hepatitis B (a disease of the liver due to infection with the hepatitis B virus).
kroničnim (dolgotrajnim) hepatitisom B (boleznijo jeter, ki je posledica okužbe z virusom hepatitisa B).
Chronic (n= 387)
Kronično obdobje (n = 387)
Chronic administration of omalizumab at dose levels of up to 250 mg/kg (at least 14 times the highest recommended clinical dose in mg/kg according to the recommended dosing table) was well tolerated in non-human primates (both adult and juvenile animals), with the exception of a dose-related and age-dependent decrease in blood platelets, with a greater sensitivity in juvenile animals.
Kronično uporabo omalizumaba v odmerkih do 250 mg/kg (kar je po tabeli priporočenega odmerjanja najmanj 14-kratnik najvišjega priporočenega kliničnega odmerka v mg/kg) so primati razen človeka (tako odrasle kot mlade živali) dobro prenašali, z izjemo zmanjšanja koncentracije trombocitov, ki je bilo odvisno od odmerka in povezano s starostjo, za katero so bile mlade živali občutljivejše.
chronic allograft nephropathy (CAN), incisional hernia
kronična nefropatija alogenskega presadka, kila na mestu vreza
Chronic Allograft Nephropathy/Interstitial Fibrosis and Tubular Atrophy (IFTA)
Kronična nefropatija alogenskega presadka/intersticijska fibroza in tubularna atrofija
Chronic co-administration of strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampicin, phenobarbital or herbal preparations containing St. John’s Wort [Hypericum perforatum]) with cabozantinib should therefore be avoided.
Kronični sočasni uporabi močnih induktorjev CYP3A4 (npr. fenitoina, karbamazepina, rifampicina, fenobarbitala ali pripravkov zeliščnega izvora iz šentjanževke [Hypericum perforatum]) s kabozantinibom se je treba zato izogniti.
Chronic daily ASA doses to accompany Brilique should be 75-150 mg (see sections 4.2 and 4.4).
Kronični dnevni odmerki ASA ob uporabi zdravila Brilique morajo biti od 75 do 150 mg (glejte poglavji 4.2 in 4.4).
Chronic diseases associated with a build-up of inflammatory cells in various organs and tissues, most commonly the lungs (sarcoidosis)
kronična bolezen, povezana s kopičenjem vnetnih celic v različnih organih in tkivih, večinoma v pljučih (sarkoidoza)
Chronic dry mouth that has resulted in periodontal disease or oral fungal infections
kronično suha usta, ki povzročijo periodontalno bolezen ali glivične okužbe v ustih,
Chronic dry mouth that has resulted in periodontal disease or oral fungal infections;
kronično suha usta, ki povzročijo periodontalno bolezen ali glivične okužbe v ustih,
Chronic graft-versus-host disease (a complication that can occur after a stem-cell or bone marrow transplantation in which the newly transplanted donor cells attack the patient’s body)
kronična reakcija presadka proti gostitelju (zaplet, ki se lahko pojavi po presaditvi matičnih celic ali kostnega mozga, ko na novo presajene darovalske celice napadajo bolnikovo telo)
Chronic HCV patients with cirrhosis may be at risk of hepatic decompensation when receiving alfa interferon therapy.
Pri bolnikih s kroničnim HCV in cirozo obstaja tveganje za pojav jetrne dekompenzacije, če prejemajo zdravljenje z alfa interferonom.
Chronic Hepatitis
preiskovanci s kroničnim hepatitisom C (n = 22)
Chronic hepatitis B – adult patients
Kronični hepatitis B – odrasli bolniki
Chronic hepatitis B: In adolescents aged 12 to < 18 years and weighing ≥ 35 kg, the recommended dose of Viread is 245 mg (one tablet) once daily, taken orally with food (see sections 4.8 and 5.1).
Kronični hepatitis B: Pri mladostnikih, starih 12 do < 18 let, s telesno maso ≥ 35 kg, je priporočeni odmerek zdravila Viread 245 mg (ena tableta) enkrat dnevno, peroralno, s hrano (glejte poglavji 4.8 in 5.1).
Chronic hepatitis B: In study GS-US-174-0115, 106 HBeAg negative and HBeAg positive patients aged 12 to < 18 years with chronic HBV infection [HBV DNA ≥ 105 copies/ml, elevated serum ALT (≥ 2 x ULN) or a history of elevated serum ALT levels in the past 24 months] were treated with tenofovir disoproxil 245 mg (as fumarate) (n = 52) or placebo (n = 54) for 72 weeks.
Kronični hepatitis B: V študiji GS-US-174-0115 so 106 bolnikov, negativnih na HBeAg in pozitivnih na HBeAg, starih 12 do < 18 let s kronično okužbo z virusom HBV [HBV DNA ≥ 105 kopij/ml, zvišano vrednostjo ALT v serumu (≥ 2 x ZMN) ali zvišano vrednostjo ALT v serumu v anamnezi v zadnjih 24 mesecih] 72 tednov zdravili s 245 mg dizoproksiltenofoviratom (v obliki dizoproksiltenofovirijevega fumarata) (n = 52) ali placebom (n = 54).
Chronic hepatitis B: Steady-state tenofovir exposure in HBV infected adolescent patients (12 to < 18 years of age) receiving an oral daily dose of tenofovir disoproxil 245 mg (as fumarate) was similar to exposures achieved in adults receiving once-daily doses of tenofovir disoproxil 245 mg (as fumarate).
Kronični hepatitis B: Izpostavljenost tenofovirju v stanju dinamičnega ravnovesja pri mladostnikih (starih 12 do < 18 let), okuženih z virusom HBV, ki so peroralno prejemali dnevni odmerek 245 mg dizoproksiltenofovirata (v obliki dizoproksiltenofovirijevega fumarata), je bila podobna kot izpostavljenost, dosežena pri odraslih, ki so prejemali enkratni dnevni odmerek 245 mg dizoproksiltenofovirata (v obliki dizoproksiltenofovirijevega fumarata).
Chronic hepatitis B: The optimal duration of treatment is unknown.
Kronični hepatitis B: Optimalno trajanje zdravljenja ni znano.
Chronic Hepatitis C - Combination therapy with ribavirin
Kronični hepatitis C - kombinirano zdravljenje z ribavirinom
Chronic hepatitis C in children and adolescent population
Kronični hepatitis C pri otrocih in mladostnikih
Chronic hepatitis C – treatment-experienced adult patients
Kronični hepatitis C – že zdravljeni odrasli bolniki
Chronic hepatitis C – treatment-naïve adult patients
Kronični hepatitis C – odrasli bolniki, ki se še niso zdravili
Chronic hepatitis in patients who are being or have been treated recently with immunosuppressive agents excluding short term corticosteroid withdrawal.
Kronični hepatitis pri bolnikih, ki se zdravijo ali so se nedavno zdravili z imunosupresivi, razen kratkotrajne ukinitve kortikosteroidov,
Chronic hepatitis in patients who are being or have been treated recently with immunosuppressive agents excluding short term corticosteroid withdrawal.
kronični hepatitis pri bolnikih, ki se zdravijo ali so se nedavno zdravili z imunosupresivi, razen po ukinitvi zdravljenja s kratko delujočimi kortikosteroidi,
Chronic hepatitis with decompensated cirrhosis of the liver.
kronični hepatitis z dekompenzirano jetrno cirozo,
Chronic idiopathic urticaria was studied as a clinical model for urticarial conditions, since the underlying pathophysiology is similar, regardless of etiology, and because chronic patients can be more easily recruited prospectively.
Kronično idiopatsko urtikarijo so proučevali kot klinični model za urtikarijska stanja, ker je osnovna patofiziologija pri vseh teh stanjih podobna, ne glede na etiologijo.
Chronic immune (idiopathic) thrombocytopenia
Kronična imunska (idiopatična) trombocitopenija
Chronic immune (idiopathic) thrombocytopenia (ITP) studies
Študije kronično imunske (idiopatične) trombocitopenije (ITP)
Chronic inflammatory condition of the lungs
kronično vnetje pljuč,
Chronic inflammatory demyelinating polyneuropathy (CIDP)*
Kronična vnetna demielinizacijska polinevropatija (CIDP)
Chronic inflammatory demyelinating polyneuropathy (CIDP).
Kronični vnetni demielinizacijski polinevropatiji (CIDP - Chronic inflammatory demyelinating polyneuropathy).
Chronic lymphocytic leukaemia
kronične limfocitne levkemije
Chronic lymphocytic leukaemia (also called “CLL”)
Kronične limfocitne levkemije (KLL)
Chronic Lymphocytic Leukaemia (CLL)
Kronična limfocitna levkemija
Chronic Lymphocytic Leukaemia (CLL) a type of cancer affecting white blood cells called lymphocytes that also involves the lymph nodes.
Kronična limfocitna levkemija (KLL), to je vrsta raka, ki prizadene bele krvne celice (limfocite), prizadene pa tudi bezgavke.
Chronic Lymphocytic Leukaemia (CLL)/Waldenström’s macroglobulinaemia (WM)
Kronična limfocitna levkemija (KLL)/Waldenstromova makroglobulinemija (WM)
Chronic lymphocytic leukaemia (CLL, in combination with chlorambucil1)
Kronična limfocitna levkemija (KLL,v kombinaciji s klorambucilom1)
Chronic lymphocytic leukaemia and Waldenström’s macroglobulinaemia
Kronična limfocitna levkemija in Waldenstromova makroglobulinemija
Chronic malabsorption syndrome
kronični malabsorpcijski sindrom
Chronic malabsorption syndrome.
kronični malabsorpcijski sindrom,
Chronic musculoskeletal disorders:
Kronična mišično-skeletna obolenja:
Chronic Myelogenous Leukaemia: 4-5 million IU/m2 daily injected subcutaneously (under the skin).
Kronična mieloična levkemija: 4 do 5 milijonov i.e./m2 na dan s subkutano (podkožno) injekcijo.
Chronic myeloid leukaemia (CML) in blast crisis.
kronično mieloično levkemijo (KML) v blastni krizi.
chronic myeloid leukaemia (CML), a cancer of the white blood cells in which granulocytes (a type of white blood cell) start growing out of control.
kronične mieloidne levkemije (KML), raka belih krvnih celic, pri katerem začnejo granulociti (vrsta belih krvnih celic) nenormalno rasti.
chronic myeloid leukaemia (CML), a cancer of the white blood cells in which granulocytes (a type of white blood cell) start growing out of control.
kronične mieloidne levkemije (KML), tj. raka belih krvnih telesc, pri katerem granulociti (vrsta belih krvnih telesc) začnejo nenadzorovano rasti.
Chronic myeloid leukaemia (CML).
kronično mieloično levkemijo (KML).
Chronic myelomonocytic leukaemia(2)(4), pancreatic adenocarcinoma(5)
kronična mielomonocitna levkemija(2)(4), adenokarcinom trebušne slinavke(5)
Chronic obstructive pulmonary disease
Kronična obstruktivna pljučna bolezen
Chronic Obstructive Pulmonary Disease
Kronična obstruktivna pljučna bolezen (KOPB)
chronic obstructive pulmonary disease,
kronična obstruktivna pljučna bolezen,
chronic obstructive pulmonary disease,
kronična obstruktivna pljučna bolezen, pnevmonitis,
chronic obstructive pulmonary disease, pneumonitis,
kronična obstruktivna pljučna bolezen,
Chronic obstructive pulmonary disease, pulmonary granuloma, vasomotor rhinitis
kronična obstruktivna pljučna bolezen, pljučni granulom, vazomotorični rinitis
Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe hypertriglyceridaemia
Kronični ali akutni pankreatitis z izjemo akutnega pankreatitisa zaradi hude hipertrigliceridemije
Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe hypertriglyceridaemia (see section 4.4).
Kronični ali akutni pankreatitis, razen akutnega pankreatitisa zaradi hude hipertrigliceridemije (glejte poglavje 4.4).
Chronic overdose and neurological disorders
Kronični prekomerni odmerek in nevrološke motnje
chronic pain
kronična bolečina;
chronic pancreatitis, peritonitis, blood amylase increased, ileus paralytic, gastrooeso- phageal reflux disease, impaired gastric emptying
pankreatitis, peritonitis, zvišanje amilaze v krvi, paralitični ileus, gastroezofa- gealna refluksna bolezen, okvarjeno praznjenje želodca
Chronic phase
Kronično obdobje
Chronic phase (n=321)
kronična faza (n=321)
Chronic phase CML (starting dose 100 mg once daily)
KML v kroničnem obdobju (začetni odmerek 100 mg enkrat na dan)
Chronic phase CML - Newly diagnosed
KML v kroničnem obdobju – bolniki z na novo diagnosticirano boleznijo
Chronic phase CML, MDS/MPD (starting dose 400 mg)
kronična faza KML, MDS/MPD (začetni
Chronic phase CML, MDS/MPD and GIST
kronična faza KML, MDS/MPD in GIST
Chronic phase n=321
kronična faza n=321
Chronic phase, Interferon failure: 532 adult patients were treated at a starting dose of 400 mg.
Kronična faza, neuspeh z interferonom: 532 odraslih bolnikov so zdravili z začetnim odmerkom 400 mg.
Chronic phase, newly diagnosed: This phase III study in adult patients compared treatment with either single-agent imatinib or a combination of interferon-alpha (IFN) plus cytarabine (Ara-C).
Kronična faza, na novo diagnosticirana: V tej študiji tretje faze z odraslimi bolniki so primerjali zdravljenje z imatinibom kot edinim zdravilom na eni strani in s kombinacijo interferona alfa (IFN) s citarabinom (Ara-C) na drugi strani.
Chronic renal failure patients
Bolniki s kronično ledvično okvaro
Chronic renal failure patients being treated with epoetin alfa should have haemoglobin levels measured on a regular basis until a stable level is achieved, and periodically thereafter.
Pri bolnikih s kroničnim ledvičnim odpovedovanjem, ki prejemajo epoetin alfa, je treba ravni hemoglobina redno meriti, dokler ni dosežena stabilna raven, potem pa v rednih časovnih intervalih.
Chronic renal failure patients on erythropoietin should have their haemoglobin (the part of a red blood cell that carries oxygen) levels measured on a regular basis until a stable level is achieved, and periodically thereafter to minimise the risk of an increase in blood pressure.
Pri bolnikih s kronično ledvično okvaro, ki dobivajo eritropoetin, je potrebno redno meriti nivo hemoglobina (del rdeče krvne celice, ki prenaša kisik) tako dolgo, da se koncentracija ustali, potem pa v enakih časovnih intervalih, da se zmanjša nevarnost zvišanja krvnega tlaka.
Chronic renal failure patients treated with Retacrit by the subcutaneous route should be monitored regularly for loss of efficacy, defined as absent or decreased response to Retacrit treatment in patients who previously responded to such therapy.
Bolnike s kronično ledvično okvaro, ki zdravilo Retacrit prejemajo subkutano, je treba redno spremljati glede izgube učinkovitosti, ki se kaže kot odsotnost ali zmanjšan odziv na zdravljenje z zdravilom Retacrit, pri tistih bolnikih, ki so se že odzivali na tako zdravljenje.
Chronic renal insufficiency
kronična ledvična insuficienca
Chronic severe hepatic disease
Hudo kronično obolenje jeter
Chronic sinusitis, fungal infection, infection, kidney infection, sinusitis, upper respiratory tract infection, urinary tract infection, bacterial urinary tract infection, meningitis aseptic
kronični sinusitis, glivična okužba, okužba, ledvična okužba, sinusitis, okužba zgornjih dihalnih poti, okužba sečil, bakterijska okužba sečil, aseptični meningitis
Chronic spontaneous urticaria (CSU)
Kronična spontana urtikarija
chronic thromboembolic pulmonary hypertension (CTEPH).
kronična trombembolična pljučna hipertenzija (CTEPH - chronic thromboembolic pulmonary hypertension)
Churg-Strauss and Hypereosinophilic syndrome have been observed in allergic asthma patients treated with Xolair.
Pri bolnikih z alergijsko astmo, ki so prejemali zdravilo Xolair, so opažali Churg-Straussov in hipereozinofilni sindrom.
Churg-Strauss and Hypereosinophilic syndrome have been observed in patients treated with Xolair.
Pri bolnikih, ki so prejemali zdravilo Xolair, so opažali Churg-Straussov in hipereozinofilni sindrom.
Churg-Strauss syndrome and hypereosinophilic syndrome
Churg-Straussov sindrom in hipereozinofilni sindrom
CI
IZ
CI 95% for HRa
IZ 95
CI = 1.08 - 2.26, p = 0.018).
RT = 1,56; 95 % IZ = 1,08 - 2,26, p = 0,018).
CI = Confidence Interval (1) 3 doses of vaccine, DNA negative and seronegative at month 0 and DNA negative at month 6 for the relevant HPV type (HPV-16 and/or HPV-18) (2) at least one dose of vaccine, irrespective of HPV DNA and serostatus at month 0.
IZ = interval zaupanja (1) 3 odmerki cepiva, DNA-negativnost in seronegativnost v mesecu 0 ter DNA-negativnost v mesecu 6 za relevantni tip HPV (HPV-16 in/ali HPV-18) (2) Vsaj en odmerek cepiva, ne glede na HPV DNA in serološko stanje v mesecu 0.
CI = confidence interval, CTX = platinum-based chemotherapy, ORR = objective response rate, OS = overall survival time, PFS = progression-free survival time
IZ = interval zaupanja; KOP = kemoterapija na osnovi platine; ORR (objective response rate) = objektivna stopnja odgovora; OS (overall survival) = celokupno preživetje, PFS (progression-free survival time) = čas preživetja brez napredovanja bolezni